Targeted radiation for limited prostate cancer spread
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving focused radiation to a small number of growing prostate cancer spots can help control the disease while you continue your current systemic treatment. It may delay the need to switch treatments and is for people whose cancer has spread to only a few places.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have prostate cancer that has spread to other parts of the body (metastatic).
- You are currently on systemic treatment (like hormone therapy or chemotherapy) for your cancer.
- You have a PET scan (PSMA PET) showing a limited number of growing cancer spots (1 to 5, or up to 10 depending on when you join).
- The growing spots can be safely treated with focused radiation.
- You do not have widespread or rapidly worsening cancer that would make focused radiation unsafe or not helpful.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
This trial tests whether giving focused radiation to limited areas of cancer growth (up to 3 spots) can help control the disease in men with castration-resistant prostate cancer. You may be eligible if your cancer is growing slowly and you are already on hormone therapy.
This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.